Bioventus Inc. (NASDAQ:BVS) Receives Average Recommendation of “Buy” from Brokerages

Shares of Bioventus Inc. (NASDAQ:BVS) have received a consensus rating of “Buy” from the six analysts that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $16.25.

BVS has been the topic of several research analyst reports. Barrington Research set a $18.00 price target on Bioventus in a report on Thursday, August 6th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Bioventus in a report on Tuesday, June 16th. Craig Hallum reiterated a “buy” rating and set a $18.00 price objective on shares of Bioventus in a research report on Thursday, August 6th. Finally, Weiss Ratings raised Bioventus from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, August 6th.

Institutional Investors Weigh In On Bioventus

Hedge funds and other institutional investors have recently made changes to their positions in the business. Nantahala Capital Management LLC lifted its stake in shares of Bioventus by 4.1% in the 4th quarter. Nantahala Capital Management LLC now owns 6,047,403 shares of the company’s stock worth $44,993,000 after purchasing an additional 236,741 shares during the period. Vanguard Group Inc. grew its position in Bioventus by 4.4% during the third quarter. Vanguard Group Inc. now owns 2,924,788 shares of the company’s stock valued at $19,567,000 after buying an additional 122,749 shares during the period. Geode Capital Management LLC grew its position in Bioventus by 1.8% during the fourth quarter. Geode Capital Management LLC now owns 1,120,238 shares of the company’s stock valued at $8,337,000 after buying an additional 19,388 shares during the period. State Street Corp increased its holdings in Bioventus by 1.7% during the fourth quarter. State Street Corp now owns 891,024 shares of the company’s stock valued at $6,629,000 after buying an additional 14,590 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in Bioventus by 14.1% during the first quarter. Dimensional Fund Advisors LP now owns 873,138 shares of the company’s stock valued at $7,971,000 after buying an additional 107,930 shares during the last quarter. Hedge funds and other institutional investors own 62.94% of the company’s stock.

Bioventus Stock Up 2.7%

BVS opened at $14.26 on Friday. The stock has a market capitalization of $1.20 billion, a price-to-earnings ratio of 18.52, a PEG ratio of 1.82 and a beta of 0.63. The firm has a 50 day moving average price of $11.36 and a 200-day moving average price of $9.90. Bioventus has a twelve month low of $6.26 and a twelve month high of $15.89. The company has a quick ratio of 1.17, a current ratio of 1.69 and a debt-to-equity ratio of 0.83.

Bioventus (NASDAQ:BVS) last issued its earnings results on Wednesday, August 5th. The company reported $0.22 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.22. Bioventus had a net margin of 9.36% and a return on equity of 28.08%. The company had revenue of $153.21 million for the quarter. Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. Equities research analysts forecast that Bioventus will post 0.79 earnings per share for the current year.

Bioventus Company Profile

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.